All In Biotech

Drug Trial Radar · NCT06194318

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

Phase 1, Placebo-controlled, Randomized, Observer-blind, First-in-human Study of Bivalent RSV Prefusion F Protein Vaccines (SCB-1019/SCB-1019T) in Healthy Adults

Last checked: Nov 19, 2026Latest source record: Jun 6, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

160

Actual

Start

Dec 13, 2023

Primary completion

Feb 26, 2025

Study completion May 7, 2025

Sponsor

Sponsor type
Industry
First posted
Jan 8, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Prevention
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 85 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

First-in-human Safety and Immunogenicity Study of SCB-1019 and SCB-1019T in Healthy Adults

Conditions

  • Respiratory Syncytial Virus Vaccination

Interventions

  • Candidate vaccine, SCB-1019Biological

    The SCB-1019 vaccine contains RSV F protein subunits from the two dominant circulating strains, A strain (SCB-1019A) and B strain (SCB-1019B). SCB-1019A and SCB-1019B are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

  • placeboBiological

    placebo

  • candidate vaccine, SCB-1019TBiological

    The SCB-1019T vaccines contain RSV F protein subunits from the two dominant circulating strains, A and B strain. Antigens are recombinant RSV F-Trimer proteins engineered by fusing the ectodomain of RSV F protein with Trimer-Tag™

  • AREXVYBiological

    AREXVY is a FDA-approved respiratory syncytial virus (RSV) vaccine for adults aged 60 and older. Developed by GSK, it targets the prefusion F glycoprotein to protect against lower respiratory tract disease caused by RSV.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Evaluate the reactogenicity of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Within 7 days after vaccination
  2. Evaluate the safety tolerability of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Within 28 days after vaccination
  3. Evaluate the safety and tolerability of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Throughout the study period, from enrollment to 6 months follow up
  4. Evaluate the safety and tolerability of SCB-1019, SCB-1019T compared with AREXVY vaccineTime frame: Screening and Day 8

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Fusion Clinical Research

    Adelaide, Southern Australia, Australia

  • Linear Clinical Research

    Nedlands, Western Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.